{# Audit 04/10/2026 : « autre » n'est pas un code de langue ; SPHAERO n'est pas l'éditeur des documents qu'elle héberge ou référence. #} {# citation_pdf_url doit mener à un PDF : un lien vers une page DOI est pénalisé par Google Scholar (avant : tout lien externe). #}
Accès ouvert · CC BY

Measuring Health-Related Quality of Life in Tuberous Sclerosis Complex – Psychometric Evaluation of Three Instruments in Individuals With Refractory Epilepsy

Article scientifique 2018 Anglais

Résumé

Tuberous Sclerosis Complex (TSC) is a rare genetic disease associated with significant disease burden and considerable impact on health-related quality of life (HRQL). Currently no disease-specific Clinical Outcome Assessments (COAs) evaluate HRQL in individuals with TSC. A multi-centre phase III study EXIST-3 (NCT01713946) assessed the efficacy and safety of two trough exposure ranges (Low exposure, LE: 3-7 ng/mL and high exposure, HE: 9-15 ng/mL) of adjunctive everolimus in patients aged 2-65 years old with TSC and refractory partial-onset seizures (N=366). Three age-specific HRQL measures were included as secondary endpoints; including: Quality of Life in Childhood Epilepsy (QOLCE; caregiver-report for aged 2-<11), the Quality of Life in Epilepsy Inventory for Adolescents-48 (QOLIE-AD-48; self-report, aged ≥11-<18), and the Quality of Life in Epilepsy Inventory-31-Problems (QOLIE-31-P; self-report, aged ≥18). Intellectual ability was evaluated using the Wechsler Non-Verbal (WNV) Scale of Ability. Post-hoc analyses were performed on the core phase primary data from EXIST-3 to evaluate the psychometric properties of the HRQL measures and calculate meaningful change estimates. Results showed that a significant subset of the trial sample (4-21 year olds) scored in the intellectual disability range, as assessed by the WNV. Psychometric analyses of the three epilepsy measures (including reliability, validity, and ability to detect change) supported the appropriateness for use in TSC. Distribution-based meaningful change estimates were generated for each HRQL measure, with estimates for the QOLIE-31-P total score largely consistent with the published literature. To our knowledge, this is the first evaluation using clinical trial data to establish the psychometric properties of the QOLCE, QOLIE-AD-48 and QOLIE-31-P for use in individuals with TSC. These findings will be useful for clinical practice and next steps in research.

Citer ce document

Vries, P. J. D., Franz, D. N., Curatolo, P., Nabbout, R., Neary, M. P., Herbst, F., Sully, K., Brohan, E., Bennett, B., & Lawson, J. A. (2018). Measuring Health-Related Quality of Life in Tuberous Sclerosis Complex – Psychometric Evaluation of Three Instruments in Individuals With Refractory Epilepsy. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2018.00964

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 30/08/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Statistiques

Consultations : 5

Téléchargements : 0